Elborn 1992.
Methods | A prospective, double‐blind, placebo controlled, randomised cross‐over design with study duration of 6 weeks. There were five participants who dropped out; we are unsure when these occurred. Two participants declined to take part in second limb of study. No washout period mentioned. |
|
Participants | Twenty participants (12 females, mean age 50 years, range 30 to 65) were studied with bronchiectasis diagnosed by bronchogram in 18 and computed tomography scan in two. No participant received a course of antibiotics for at least 8 weeks prior to the study. Exclusion: participants with hypogammaglobulinaemia, cystic fibrosis, ABPA or primary ciliary dyskinesia, as well as those taking OCS or ICS. |
|
Interventions | Inhaled beclomethasone dipropionate 750 µg twice daily by MDI or placebo for 6 weeks. | |
Outcomes |
|
|
Notes | Cross‐over design with no washout period. Separate results of first arm not available. Data not included in analysis. No funding source mentioned, though acknowledgement for ICS was given to Allen and Hanburys. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | No information was provided within the published article about generation of randomisation. |
Allocation concealment (selection bias) | Unclear risk | No information about concealment was reported in the article. |
Blinding (performance bias and detection bias) All outcomes | Low risk | Quote: "double‐blinded" and "matched placebo". |
Incomplete outcome data (attrition bias) All outcomes | High risk | There were 5 patients who dropped out; we are unsure when these occurred. Two patients declined to take part in second arm of study. |
Selective reporting (reporting bias) | Low risk | No suggestion that selective reporting may have been done. |
Other bias | High risk | Cross‐over design with no washout period. Separate results of first arm not available. |